Streetbeat News

Analyst Ratings

EWCZ

Truist Securities analyst Scot Ciccarelli has maintained a 'Buy' rating on European Wax Center (NASDAQ:EWCZ), but lowered the price target from $20 to $16.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:33 pm

DIOD

Truist Securities analyst William Stein has maintained a 'Buy' rating on Diodes (NASDAQ:DIOD) but lowered the price target from $93 to $72.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:32 pm

DVN

Truist Securities analyst Neal Dingmann has maintained a 'Buy' rating on Devon Energy (NYSE:DVN), but lowered the price target from $68 to $65.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:31 pm

BIGC

Truist Securities analyst Terry Tillman has maintained a 'Hold' rating on BigCommerce Holdings (NASDAQ:BIGC) and lowered the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:30 pm

ARRY

Truist Securities analyst Jordan Levy has maintained a 'Buy' rating on Array Technologies (NASDAQ:ARRY) but lowered the price target from $38 to $30.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:29 pm

ABUS

BRNS

Barinthus Biotherapeutics (BRNS) announced data from two HBV clinical trials at The American Association for the Study of Liver Diseases. The data includes results from a Phase 2b trial of VTP-300 combined with a low-dose anti-PD-1 antibody and standard-of-care (SoC) nucleos(t)ide analogue (NUC) therapy. Additionally, interim data from a Phase 2a trial combining Arbutus Biopharma Corporation’s (ABUS) RNAi therapeutic candidate, imdusiran, with Barinthus Bio’s VTP-300 and SoC NUC therapy was presented. The initial data shows meaningful reductions of HBsAg levels.

Portfolio Pulse from Charles Gross

November 09, 2023 | 9:27 pm

ANGI

Truist Securities analyst Youssef Squali has maintained a 'Buy' rating on Angi (NASDAQ:ANGI) but lowered the price target from $5 to $4.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:27 pm

AFRM

Truist Securities analyst Andrew Jeffrey maintains a 'Buy' rating on Affirm Holdings (NASDAQ:AFRM) and raises the price target from $28 to $33.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:26 pm

ONTO

Onto Innovation's Q3 adjusted earnings per share of $0.96 beat the analyst consensus estimate of $0.95 by 1.05%. However, the company's quarterly sales of $207.19 million missed the analyst consensus estimate of $215.20 million by 3.72%. This represents a 28.89% decrease in earnings and an 18.51% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:24 pm

ASLE

Truist Securities analyst Michael Ciarmoli has maintained a 'Buy' rating on AerSale (NASDAQ:ASLE) but lowered the price target from $23 to $19.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:23 pm